Crypto7o 🔥🚨💎

$OLOX Shorts are officially trapped and bleeding out daily. 🩸🐻 The Cost to Borrow (CTB) is currently pinned at an absolutely massive 640.52% and there are only 20k shares even left to short. They are paying a massive premium just to hold this price down on literal ghost volume (single-digit volume in the pre-market?!). They are praying retail gets bored and sells, because the minute that 10-K drops, or any real volume steps in, this float locks up and the shorts are going to get absolutely vaporized trying to cover. Patience pays. Holding the line. 💎🙌 🚀 #ShortSqueeze #OLOX

Available short shares on $OLOX just fell off a cliff down to literally 600 shares. The borrow fee is still maxed at 640%. Shorts are scraping the absolute bottom of the barrel right now. Plus, the company officially stated they expect to drop the Q1 10-Q today. If that hits the wire with zero liquidity left to short, this float is going to violently lock up. 💎🙌 #stocks #investing #shorts #news

For traders looking for a solid group, I highly recommend checking out Adachi Stocks on Discord. It is a really clean setup with dedicated hubs for day trading, long term plays, and live callouts. They actually have strict trading rules against shouting blind entry prices or creating random FOMO, so the quality of the charts and facts shared in the channels is top tier. It is completely free to join if you want to check it out. discord.com/invite/VDHRx6AmJ…

Check out this $OLOX setup right now. it is definitely due for an explosive move! 🚀📈 The regular session volume is starting to wake up, and the price is holding beautifully right at the $10.00 psychological level, sitting comfortably above the $9.94 intraday VWAP support. On the 5-minute chart, the Bollinger Bands are completely coiling and pinching tight. This level of extreme compression always leads to a massive, violent expansion. With short availability still locked at ZERO and a brutal 450% borrow fee, the structural setup is a literal pressure cooker. Watch the tape closely for a heavy volume push over the morning high of 10.29 to ignite the next major squeeze wave. The fuse is lit. 💥 Scanners ready!

$GNPX Timeline Going Forward As of May 23, for anyone trying to keep up with what’s coming next, here’s the timeline the way I’m looking at it. May 29–June 2: ASCO 2026 REQORSA biomarker data / TROP2 + PTEN angle. This is actual clinical biomarker data, not just early lab research. June 18: Annual meeting / proxy vote Worth watching because of the reverse split proposal and the other shareholder votes. By June 30: Acclaim-1 & Acclaim-3 enrollment target window Genprex has said they’re aiming for interim enrollment milestones in H1 2026. July–December 2026: Bigger clinical window Interim analyses are expected for Acclaim-1 and Acclaim-3. GPX-002: The FDA meeting already happened. Next up should be tox studies, manufacturing work, and more clarity on the IND path. No exact timing yet though. The 10-Q also showed cash runway into H2 2027, so the company finally has some breathing room. Runway is there. Pipeline is moving. Now management just has to deliver. NFA #biotech #stocks #cancer #diabetes

$GNPX 10-Q is out. I actually see the runway into H2 2027 as a big positive. Yes, they used the ATM. Everyone already knew dilution was happening, the chart has been screaming it for months. But now Genprex has time. GPX-002, tox studies, manufacturing, ASCO, REQORSA, clinical progress. The cash fear is reduced. Now it’s simple: Management needs to execute and rebuild trust. No more excuses. NFA app.quotemedia.com/data/down…

Look at that after hours close. Somebody is loading up right at the buzzer before the presentation later today. The comeback is definitely on. Nfa $GNPX #ASGCT2026 #GeneTherapy #Diabetes #Biotech

$GNPX The 89th minute comeback. Being a Genprex investor right now feels exactly like being 5-0 down in the 89th minute of a cup final. Rain pouring. Fans leaving the stadium. Manager looks finished. 😂 We are all exhausted, battered, and questioning every life decision. But today is Wednesday May 13th, and we finally get the GPX-002 diabetes data at ASGCT. I’m not saying it moves. I’m not saying miracles happen. But this is one of the few real things we’ve had to watch in a while. I’m still holding the line. Who’s standing with me? Drop your wildest predictions below 👀 NFA #ASGCT2026 #GeneTherapy #Diabetes #Biotech @genprex

$GNPX #ASGCT is worth watching, but the poster alone isn’t enough now. The real question is what Genprex says next on GPX-002: tox studies, manufacturing, and the IND path. That’s what could actually matter. No more noise. Execution now. #GeneTherapy #Diabetes #Biotech #ASGCT2026

$GNPX ASGCT week is here. Genprex collaborators are presenting positive preclinical data for GPX-002 in Type 2 diabetes at the 2026 ASGCT Annual Meeting in Boston. Not calling miracles here, holders have been through enough. But the diabetes side is still moving. Let’s see if the market finally pays attention. #GeneTherapy #Diabetes

$RDAC is one of those ugly setups people ignore… until it randomly does 200% in their face. Filing shows: 5,750,000 shares subject to redemption 5,715,609 redeemed = 34,391 public shares remaining That’s the whole float angle. Not saying it’s safe. The spread is nasty and the book is thin. But this already hit $23.99 recently, and now it’s back sitting in the $8s while everyone is chasing $AIOS. If low-float China/SPAC sympathy gets volume again, $RDAC is one I’m watching closely. Tiny float + proven runner = dangerous either way. $RDAC $AIOS $UONE $UK

Genprex signed a new Sponsored Research Agreement with MD Anderson to dig deeper into the TROP2 and PTEN biomarkers for REQORSA (TUSC2 gene therapy). This is a direct follow up to yesterday’s AACR poster. They already showed that low TROP2 + high PTEN in the tumour can predict primary resistance (i.e. the therapy probably won’t work well for those patients). Basically, they want to figure out exactly why some patients respond incredibly well to the therapy (like the one patient who has been in remission for 42 months) and why others don't. If they lock this down, they can cherry pick the perfect patients for their Acclaim trials moving forward, which massively increases the chances of trial success. Loving the precision oncology approach here. 🚀 Ryan Confer and the team are basically saying this could help make future trials way more successful by only treating the people most likely to benefit. Science side keeps getting stronger, even if the share price isn’t showing it yet 😂 Still holding my bag. NFA obviously, but this feels like the right direction. #gnpx #biotech #stocknews #stocks #Markets prnewswire.com/news-releases…

Watched this fantastic 33-minute interview with Genprex CEO Ryan Confer on the future of gene therapy. He walks through how their lead candidate Reqorsa delivers the TUSC2 tumor suppressor gene to fight lung cancer (NSCLC & SCLC) from multiple angles — triggering cancer cell death, boosting the immune system, and doing it with far less toxicity than traditional chemo. He also covers their early diabetes program that could reprogram pancreatic cells and potentially eliminate insulin dependence. It’s optimistic, science-focused, and gives the big-picture vision behind what they’re building. Really worth the watch if you’re into $GNPX or personalized medicine. Full video (uploaded a few weeks ago): youtu.be/4vPEED2P75I What did you think if you’ve seen it? 👀 #GNPX #GeneTherapy #Reqorsa